- Family Member
- Posts: 93
- Joined: Sat Jul 10, 2004 2:00 pm
- Location: Minnesota, USA
The Therapeutic Goods Administration in Australia has awarded Aimspro “Orphan Drug Status” in the treatment of Krabbe’s Leukodystrophy, a serious inherited disease of the nervous system. This condition is characterised by the failure of the myelin sheaths surrounding nerve fibres to develop normally.
Formal controlled, double blinded trials will now take place in Australia to assess the medication’s efficacy in treating this rare, disabling condition.
- Similar Topics
- Last post